ALNYLAM PHARMACEUTICALS, INC. Financials Alnylam Pharmaceuticals, Inc.
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 143.3 USD | -0.28% |
|
-0.76% | -25.13% |
| 08/04 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| 08/04 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,840 | 15,100 | 20,282 | 29,238 | 24,021 | 18,122 | - | - |
| Enterprise Value (EV) 1 | 12,293 | 13,417 | 18,522 | 28,132 | 23,979 | 17,782 | 17,523 | 17,217 |
| P/E ratio | -14.2 x | -17.4 x | -23.6 x | -25.6 x | -54.4 x | -35 x | -81.8 x | 72.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 58.4 x | 30.6 x | 24 x | 28.2 x | 13.1 x | 9.78 x | 7.99 x | 5.88 x |
| EV / Revenue | 55.9 x | 27.2 x | 21.9 x | 27.1 x | 13.1 x | 9.6 x | 7.72 x | 5.59 x |
| EV / EBITDA | -13.9 x | -16.9 x | -28 x | -38 x | - | -49 x | -1,216 x | 21.7 x |
| EV / FCF | -29.4 x | -19.6 x | -25.8 x | -45.9 x | 572 x | -76.2 x | -635 x | 25.6 x |
| FCF Yield | -3.41% | -5.11% | -3.88% | -2.18% | 0.17% | -1.31% | -0.16% | 3.91% |
| Price to Book | 8.98 x | 14.9 x | 34.6 x | -186 x | -109 x | 5,732 x | -176 x | 50.9 x |
| Nbr of stocks (in thousands) | 1,11,490 | 1,16,181 | 1,19,601 | 1,23,028 | 1,25,493 | 1,26,452 | - | - |
| Reference price 2 | 115.2 | 130.0 | 169.6 | 237.6 | 191.4 | 143.3 | 143.3 | 143.3 |
| Announcement Date | 06/02/20 | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 219.8 | 492.9 | 844.3 | 1,037 | 1,828 | 1,853 | 2,269 | 3,079 |
| EBITDA 1 | -885.1 | -793.7 | -661.1 | -740.6 | - | -363.2 | -14.41 | 793.2 |
| EBIT 1 | -939.4 | -828.4 | -708.7 | -785.1 | -282.2 | -414.5 | -171 | 351.3 |
| Operating Margin | -427.5% | -168.09% | -83.93% | -75.68% | -15.43% | -22.36% | -7.53% | 11.41% |
| Earnings before Tax (EBT) 1 | -885.3 | -855.6 | -852.1 | -1,127 | -433.5 | -500 | -240.9 | 275.7 |
| Net income 1 | -886.1 | -858.3 | -852.8 | -1,131 | -440.2 | -514.7 | -242.9 | 257.1 |
| Net margin | -403.24% | -174.15% | -101.01% | -109.04% | -24.08% | -27.77% | -10.7% | 8.35% |
| EPS 2 | -8.110 | -7.460 | -7.200 | -9.300 | -3.520 | -4.100 | -1.751 | 1.980 |
| Free Cash Flow 1 | -418.6 | -685.3 | -718.1 | -613.3 | 41.94 | -233.5 | -27.59 | 672.5 |
| FCF margin | -190.48% | -139.05% | -85.05% | -59.12% | 2.29% | -12.6% | -1.22% | 21.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 84.78% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 261.55% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 06/02/20 | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 187.6 | 258.5 | 213.3 | 224.8 | 264.3 | 335 | 319.3 | 318.8 | 750.5 | 439.7 | 426.9 | 461.4 | 464.1 | 487.7 | 504.8 |
| EBITDA 1 | -169.9 | -183.2 | -137.3 | -181.6 | -247.4 | -174.3 | -135.7 | -216.7 | 227.2 | - | -123.4 | -110.4 | -75.4 | -52.6 | - |
| EBIT 1 | -181.7 | -194.6 | -146.7 | -191.7 | -258 | -188.6 | -149.8 | -229.8 | 213.9 | -116.4 | -117.5 | -97.75 | -113.3 | -106 | -110.9 |
| Operating Margin | -96.83% | -75.26% | -68.8% | -85.26% | -97.63% | -56.3% | -46.92% | -72.1% | 28.5% | -26.47% | -27.53% | -21.19% | -24.42% | -21.74% | -21.97% |
| Earnings before Tax (EBT) 1 | -204.2 | -260.3 | -239.4 | -274.7 | -405.9 | -207 | -172.4 | -274.2 | 150.7 | -137.7 | -133.2 | -114.3 | -132.5 | -124.3 | -128.1 |
| Net income 1 | -204.5 | -258.5 | -240.3 | -277.4 | -405.9 | -207.5 | -174.1 | -276 | 147.8 | -137.9 | -143.8 | -127.1 | -139.6 | -121 | -129.2 |
| Net margin | -109% | -99.97% | -112.7% | -123.39% | -153.58% | -61.93% | -54.53% | -86.59% | 19.69% | -31.35% | -33.68% | -27.54% | -30.07% | -24.8% | -25.59% |
| EPS 2 | -1.720 | -2.160 | -2.000 | -2.290 | -3.320 | -1.680 | -1.400 | -2.210 | 1.180 | -1.100 | -1.166 | -1.039 | -1.100 | -0.9669 | -0.9947 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/10/21 | 10/02/22 | 28/04/22 | 28/07/22 | 27/10/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 15/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 547 | 1,683 | 1,760 | 1,105 | 41.4 | 340 | 599 | 905 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -419 | -685 | -718 | -613 | 41.9 | -234 | -27.6 | 673 |
| ROE (net income / shareholders' equity) | -53.4% | -69.9% | -106% | -526% | - | -287% | -29.3% | 68.8% |
| ROA (Net income/ Total Assets) | -44.6% | -29.6% | -24.2% | -31.5% | -11.9% | -7.99% | -3.01% | 5.2% |
| Assets 1 | 1,985 | 2,901 | 3,525 | 3,595 | 3,688 | 6,443 | 8,063 | 4,945 |
| Book Value Per Share 2 | 12.80 | 8.730 | 4.890 | -1.280 | -1.750 | 0.0300 | -0.8200 | 2.820 |
| Cash Flow per Share 2 | - | -5.350 | -5.420 | -4.450 | 0.8300 | -0.7500 | 2.600 | 5.910 |
| Capex 1 | 140 | 70.4 | 76.4 | 72.1 | 62.2 | 88.4 | 97.5 | 120 |
| Capex / Sales | 63.78% | 14.28% | 9.05% | 6.95% | 3.4% | 4.77% | 4.3% | 3.91% |
| Announcement Date | 06/02/20 | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
143.3
USD
Average target price
219.9
USD
Spread / Average Target
+53.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.13% | 18.12B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B | |
| -16.98% | 10.07B |
- Stock Market
- Equities
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
